AstraZeneca’s (AZN) Sell Rating Reiterated at UBS Group
UBS Group reissued their sell rating on shares of AstraZeneca (LON:AZN) in a research report released on Thursday, Borsen Zeitung reports. They currently have a GBX 5,400 ($70.56) price objective on the biopharmaceutical company’s stock.
Other analysts have also issued research reports about the stock. Jefferies Financial Group reissued a buy rating and issued a C$15.00 price target on shares of Aphria in a research report on Friday, May 24th. Citigroup set a $13.00 target price on shares of e.l.f. Beauty and gave the company a hold rating in a report on Monday, May 13th. Goldman Sachs Group set a €76.30 ($88.72) target price on shares of Stroeer SE & Co KGaA and gave the company a buy rating in a report on Thursday. Shore Capital reissued a buy rating on shares of AstraZeneca in a report on Thursday. Finally, Liberum Capital reissued a sell rating on shares of Pendragon in a report on Thursday, June 27th. Three analysts have rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of GBX 6,582.35 ($86.01).
LON AZN opened at GBX 7,005 ($91.53) on Thursday. The company has a 50 day simple moving average of GBX 6,385.84. AstraZeneca has a 12-month low of GBX 5,312 ($69.41) and a 12-month high of GBX 6,634 ($86.68). The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. The company has a market capitalization of $90.58 billion and a price-to-earnings ratio of 36.87.
In other news, insider Marc Dunoyer bought 8,500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were acquired at an average price of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82). Also, insider Philip A. J. Broadley bought 520 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were purchased at an average cost of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Why do earnings reports matter?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.